215 related articles for article (PubMed ID: 9668334)
1. 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).
Sanders DB
Ann N Y Acad Sci; 1998 May; 841():811-6. PubMed ID: 9668334
[No Abstract] [Full Text] [Related]
2. 3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis.
Sanders DB; Howard JF; Massey JM
Ann N Y Acad Sci; 1993 Jun; 681():588-90. PubMed ID: 8357206
[No Abstract] [Full Text] [Related]
3. [3,4-diaminopyridine in the treatment of myasthenic syndromes. Practical aspects].
Vílchez JJ; Casanova B; Monte E
Med Clin (Barc); 1996 Jan; 106(1):37-8. PubMed ID: 8750543
[No Abstract] [Full Text] [Related]
4. 3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.
Molgó J; Guglielmi JM
Pflugers Arch; 1996; 431(6 Suppl 2):R295-6. PubMed ID: 8739381
[TBL] [Abstract][Full Text] [Related]
5. 3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome.
Lee MK; Sunwoo IN; Kim SM
J Clin Neurosci; 2018 Apr; 50():194-198. PubMed ID: 29402568
[TBL] [Abstract][Full Text] [Related]
6. 3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials.
Zhang N; Hong D; Ouyang T; Meng W; Huang J; Li M; Hong T
BMC Neurol; 2021 Sep; 21(1):371. PubMed ID: 34563155
[TBL] [Abstract][Full Text] [Related]
7. Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine.
Smith AG; Wald J
Neurology; 1996 Apr; 46(4):1143-5. PubMed ID: 8780107
[TBL] [Abstract][Full Text] [Related]
8. Treatment for Lambert-Eaton myasthenic syndrome.
Keogh M; Sedehizadeh S; Maddison P
Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD003279. PubMed ID: 21328260
[TBL] [Abstract][Full Text] [Related]
9. Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.
Oh SJ; Shcherbakova N; Kostera-Pruszczyk A; Alsharabati M; Dimachkie M; Blanco JM; Brannagan T; Lavrnić D; Shieh PB; Vial C; Meisel A; Komoly S; Schoser B; Sivakumar K; So Y;
Muscle Nerve; 2016 May; 53(5):717-25. PubMed ID: 26852139
[TBL] [Abstract][Full Text] [Related]
10. Stimulated single-fiber electromyography in Lambert-Eaton myasthenic syndrome before and after 3,4-diaminopyridine.
Sadeh M; River Y; Argov Z
Muscle Nerve; 1997 Jun; 20(6):735-9. PubMed ID: 9149081
[TBL] [Abstract][Full Text] [Related]
11. Effect of 3,4-diaminopyridine on the time course of decay of compound muscle action potential augmentation in the Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J; Mills KR
Muscle Nerve; 1998 Sep; 21(9):1196-8. PubMed ID: 9703446
[TBL] [Abstract][Full Text] [Related]
12. The myasthenic syndrome: anaesthesia in a patient treated with 3.4 diaminopyridine.
Telford RJ; Hollway TE
Br J Anaesth; 1990 Mar; 64(3):363-6. PubMed ID: 1970263
[TBL] [Abstract][Full Text] [Related]
13. Amifampridine for the Management of Lambert-Eaton Myasthenic Syndrome: A New Take on an Old Drug.
Yoon CH; Owusu-Guha J; Smith A; Buschur P
Ann Pharmacother; 2020 Jan; 54(1):56-63. PubMed ID: 31319693
[No Abstract] [Full Text] [Related]
14. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.
Lundh H; Nilsson O; Rosén I; Johansson S
Acta Neurol Scand; 1993 Aug; 88(2):136-40. PubMed ID: 8213058
[TBL] [Abstract][Full Text] [Related]
15. Treatment for Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J
Cochrane Database Syst Rev; 2003; (2):CD003279. PubMed ID: 12804456
[TBL] [Abstract][Full Text] [Related]
16. Neurogenic bladder in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine.
Satoh K; Motomura M; Suzu H; Nakao Y; Fujimoto T; Fukuda T; Nakane S; Nakamura T; Eguchi K
J Neurol Sci; 2001 Jan; 183(1):1-4. PubMed ID: 11166786
[TBL] [Abstract][Full Text] [Related]
17. Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine.
Chan KY; Chang RS; Lau VW; Chan ML; Lai T
Ann Palliat Med; 2016 Oct; 5(4):311-314. PubMed ID: 27506750
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of Lambert-Eaton syndrome with 3,4- diaminopyridine and pyridostigmine].
Yachachi Monfort A; Cortés Pastor F; de la Rubia Nieto A; Sánchez Garre MJ
Farm Hosp; 2007; 31(4):254-6. PubMed ID: 18052623
[No Abstract] [Full Text] [Related]
19. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.
Wirtz PW; Titulaer MJ; Gerven JM; Verschuuren JJ
Expert Rev Clin Immunol; 2010 Nov; 6(6):867-74. PubMed ID: 20979551
[TBL] [Abstract][Full Text] [Related]
20. Cardiac arrest following an iatrogenic 3,4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome.
Boerma CE; Rommes JH; van Leeuwen RB; Bakker J
J Toxicol Clin Toxicol; 1995; 33(3):249-51. PubMed ID: 7760450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
